Daily Cardiology Research Analysis
Three impactful cardiology studies emerged: a nationwide cohort showed that admission of NSTEMI patients to specialty cardiology wards confers persistent 1- and 10-year survival benefits; a 22-center real-world study (MANIFEST-REDO) revealed pulmonary vein reconnections are common after pulsed field ablation, informing expectations and redo strategies; and a prospective imaging-informed reclassification of Type 2 MI stratified risk and reduced overdiagnosis, identifying those most likely to bene
Summary
Three impactful cardiology studies emerged: a nationwide cohort showed that admission of NSTEMI patients to specialty cardiology wards confers persistent 1- and 10-year survival benefits; a 22-center real-world study (MANIFEST-REDO) revealed pulmonary vein reconnections are common after pulsed field ablation, informing expectations and redo strategies; and a prospective imaging-informed reclassification of Type 2 MI stratified risk and reduced overdiagnosis, identifying those most likely to benefit from treatment.
Research Themes
- Health system organization and long-term outcomes in NSTEMI
- Durability and redo strategies after pulsed field ablation in atrial fibrillation
- Imaging-informed reclassification of Type 2 myocardial infarction
Selected Articles
1. Implications of a new clinical classification of acute myocardial infarction.
In a prospective cohort of 100 patients initially labeled as Type 2 MI, imaging-guided reclassification identified 25 spontaneous MI, 31 secondary MI, and 44 without MI. Secondary MI patients had substantially worse outcomes over 4.4 years, whereas nearly half had no evidence of MI, suggesting overdiagnosis under current criteria.
Impact: Provides an objective, imaging-informed framework to resolve ambiguity in Type 2 MI, reducing overdiagnosis and targeting high-risk patients for therapy.
Clinical Implications: Adopt cardiac imaging to reclassify suspected Type 2 MI: avoid unnecessary antithrombotics in patients without MI, and intensify secondary prevention in those with secondary MI who have high event rates.
Key Findings
- Imaging-based classification re-labeled 44/100 patients as having no MI despite initial Type 2 MI diagnosis.
- Secondary MI subgroup (31/100) had markedly higher composite events over 4.4 years (55% vs 16% vs no-MI).
- Secondary MI patients were older, with more risk factors and higher troponin concentrations.
Methodological Strengths
- Prospective design with mandated multimodality cardiac imaging (angiography and CMR/echo).
- Objective, prespecified classification criteria and long median follow-up (4.4 years).
Limitations
- Single-cohort, relatively small sample size (n=100) limits generalizability.
- Management strategies based on reclassification were not randomized.
Future Directions: Multicenter trials to validate the classification, test imaging-guided management algorithms, and quantify impacts on therapy selection and outcomes.
AIMS: The diagnostic criteria for Type 2 myocardial infarction identify a heterogeneous group of patients with variable outcomes and no clear treatment implications. We aimed to determine the implications of a new clinical classification for myocardial infarction with more objective diagnostic criteria using cardiac imaging. METHODS AND RESULTS: In a prospective cohort study, patients with Type 2 myocardial infarction underwent coronary angiography and cardiac magnetic resonance imaging or echocardiography. The new classification was applied to identify (i) spontaneous myocardial infarction due to acute coronary pathology, (ii) secondary myocardial infarction precipitated by acute illness in the presence of obstructive coronary artery disease, a new regional wall motion abnormality, or infarct-pattern scarring, and (iii) no myocardial infarction in the absence of obstructive disease or new myocardial abnormality. In 100 patients (65 years, 43% women) with Type 2 myocardial infarction, the new classification identified 25 and 31 patients with spontaneous and secondary myocardial infarction, respectively, and 44 without myocardial infarction. Compared with patients without myocardial infarction, those with secondary myocardial infarction were older, had more risk factors, and had higher troponin concentrations (P < 0.05 for all). During a median follow-up of 4.4 years, death, myocardial infarction, or heart failure hospitalization was more common in secondary myocardial infarction compared with those without myocardial infarction [55% (17/31) vs. 16% (7/44), P < 0.001]. CONCLUSION: A new clinical classification of myocardial infarction informed by cardiac imaging would reduce the diagnosis of myocardial infarction in acute illness and identify those patients at highest risk who are most likely to benefit from treatment. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT03338504.
2. Repeat procedures after pulsed field ablation for atrial fibrillation: MANIFEST-REDO study.
In a 22-center real-world cohort (n=427) undergoing redo after index PFA, PV reconnections were observed in ~28–33% per vein, with 45% showing durable isolation of all veins at redo. Freedom from AF/AT after redo was 65% at a median 284 days, and persistent AF at recurrence predicted post-redo recurrence.
Impact: Provides the first large-scale, multicenter reality check on PFA durability and redo outcomes, informing operator expectations, follow-up, and strategy selection.
Clinical Implications: Counsel AF patients that PV reconnection after PFA is common; consider systematic mapping/imaging to optimize index procedures; tailor surveillance and redo strategies, especially for patients with persistent AF recurrences.
Key Findings
- PV reconnection rates at redo were 28–33% per vein; 45% of patients had all PVs durably isolated.
- Primary effectiveness after redo (AF/AT freedom without AADs post-blanking) was 65% at median 284 days.
- Persistent AF as the recurrent arrhythmia after index PFA predicted recurrence after redo (HR 1.241; P=0.045).
- Procedural complications at redo were low (2.8%).
Methodological Strengths
- Large multicenter cohort across 22 centers with standardized reporting.
- Clinically relevant endpoints with objective reconnection assessment at redo.
Limitations
- Selection bias: only patients with clinical recurrence underwent redo.
- Heterogeneity in mapping and procedural techniques across centers.
Future Directions: Prospective studies to optimize index PFA lesion sets, evaluate adjunct imaging/mapping, and standardize redo algorithms; comparative outcomes versus thermal ablation.
AIMS: Initial clinical studies of pulsed field ablation (PFA) to treat atrial fibrillation (AF) indicated a >90% durability rate of pulmonary vein isolation (PVI). However, these studies were largely conducted in single centres and involved a limited number of operators. We aimed to describe the electrophysiological findings and outcomes in patients undergoing repeat ablation after an initial PF ablation for AF. METHODS AND RESULTS: In the MANIFEST-REDO study, we investigated patients who underwent repeat ablation due to clinical recurrence-AF or atrial tachycardia (AT)-following first-ever PVI with a pentaspline PFA catheter (Farawave, Boston Scientific Inc.). At 22 centres, 427 patients (age 64 ± 11 years; 37% female) were included. Of note, the recurrent arrhythmia leading to the repeat ablation was paroxysmal AF (51%), persistent AF (30%), or AT (19%). At the repeat procedure, the PV reconnection rates were 30% (left superior pulmonary vein), 28% (left inferior pulmonary vein), 33% (right superior pulmonary vein), and 32% (right inferior pulmonary vein). In 45% of patients, all PVs were durably isolated at the beginning of the repeat procedure, with the previous use of any imaging or mapping modality being univariately associated with durable PVI. After a post-redo follow-up period of 284 (90-366) days, the primary effectiveness endpoint (freedom from documented AF/AT lasting ≥30 s after 3-month blanking without class I/III antiarrhythmic drugs or symptoms) was achieved in 65% of patients, with significant differences between groups (PAF 65% vs. PersAF 56% vs. AT 76%; P = 0.04). Persistent AF as recurrent arrhythmia after the initial PFA ablation predicted AT/AF recurrence after repeat ablation [hazard ratio 1.241 (95% confidence interval 1.534-1.005); P = 0.045]. The procedural complication rate was 2.8%. CONCLUSION: In repeat procedures for AF/AT performed after an index procedure with PFA for AF, PV reconnections are not uncommon. Repeat procedures can be performed safely and with an acceptable subsequent success rate.
3. The impact of specialist cardiology inpatient care on the long-term outcomes of non-ST-segment elevation myocardial infarction (NSTEMI): A nationwide cohort study.
Among 425,205 NSTEMI patients in the UK, admission to specialty cardiology wards was associated with lower 1-year (aHR 0.84) and 10-year mortality (aHR 0.88). Geographic variation suggests substantial lives could be saved by increasing specialty ward admissions toward the 80% MINAP target.
Impact: Quantifies long-term survival benefits of specialist inpatient cardiology care at a national scale, highlighting system-level targets that could save lives.
Clinical Implications: Prioritize NSTEMI admissions to specialty cardiology wards; align regional systems to meet the 80% target; ensure evidence-based therapies are implemented during index care.
Key Findings
- Admission to specialty cardiology wards was associated with lower 1-year (aHR 0.84) and 10-year mortality (aHR 0.88).
- Specialty ward patients were more likely to receive statins and beta-blockers at index care.
- Substantial regional variation in specialty ward admission rates; modeling suggests >1700 deaths could be avoided by reaching 80% admissions.
Methodological Strengths
- Very large, nationwide linked registry with long-term mortality follow-up.
- Robust multivariable Cox modeling with multiple imputation.
Limitations
- Observational design subject to confounding by indication and residual bias.
- Differences in processes of care may not be fully captured.
Future Directions: Health services interventions to increase specialty ward access; evaluate pathways, staffing, and bed capacity; quasi-experimental analyses to infer causality.
BACKGROUND: Specialist cardiac care has been shown to reduce inpatient mortality following non-ST segment myocardial infarction (NSTEMI), but whether this benefit extends beyond index admission is unclear. METHODS: Using the linked Myocardial Ischaemia National Audit Project (MINAP) registry, and Office for National Statistics mortality recording, we included 425,205 NSTEMI patients admitted to UK hospitals, between January 2005 and March 2019 that survived to discharge. 217,964 (52 %) were admitted to a specialty cardiac ward. Multivariable Cox-regression models were applied to imputed data to estimate Hazard Ratios for mortality over our study period. RESULTS: Patients admitted to specialty cardiology wards were younger (70 years vs. 75), less often female (32 % vs. 40 %) but more often received statins (86 % vs. 84 %) or beta-blockers (83 % vs. 77 %) (all P < 0.001). One-year (aHR:0.84, 95 % CI 0.83-0.86), and ten-year mortality (aHR: 0.88, 95 % CI 0.87-0.89) were lower in patients admitted to specialty cardiac wards, compared to admitted elsewhere (all P < 0.001). There was significant geographic variation in the proportion admitted to speciality cardiac wards (London 59 % vs. East of England 43 %), with over 1700 deaths potentially avoided if the MINAP target of 80 % was reached. CONCLUSION: Patients admitted to a cardiac ward had significantly lower mortality compared to alternate wards persisting up to ten-years. There is wide regional variation in the proportion of patients who received specialist cardiology care during their admission and an opportunity exists for lives saved if the proportion of NSTEMI patients admitted to a cardiac ward were to reach the MINAP target of 80 %.